Market close: Pacific Edge slumps amid weak NZ sharemarket

Market close: Pacific Edge slumps amid weak NZ sharemarket

Cancer diagnostic company Pacific Edge slumped 55% after failing to get the backing for continued United States Medicare payments for its Cxbladder tests,...

Pacific Edge cancer diagnosis firm shares plunge after US decision

Otago cancer diagnostics company Pacific Edge has lost key US Medicare coverage for its flagship test, and it's share price has fallen 63 percent in early trading. But it says it may appeal the US decision, or pursue legal action.

'Flawed analysis': Pacific Edge shares tumble after Medicare decision

Pacific Edge's flagship product has had its coverage revoked by US government health insurer Medicare. Photo: Supplied A Dunedin-based cancer diagnostics company’s share prices halved after a decision by a United States healthcare provider to revoke coverage for its flagship product.